BRICKELL BIOTECH BBI 深 沪
等待开盘 09-04 09:30:00 美东时间
2.35
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 2.35
- 总市值 675.39万
- 52周最高 36.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.21
- 委 比 0.00%
- 总股本 287.40万
- 历史最高 225.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 4.185
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET
BridgeBio Pharma将于2025年9月10日美国东部时间上午8点举办投资者网络研讨会，介绍其用于治疗遗传性低钙血症1型（ADH1）的候选药物encaleret。研讨会将由NIH的Rachel Gafni博士主持，她将详细介绍ADH1的病理、未满足的医疗需求及encaleret的治疗潜力。此外，BridgeBio的高管团队还将汇报encaleret的临床开发进展及其3期CALIBRATE研究的最新情况，预计2025年秋季发布顶线结果。投资者可访问公司网站参与实时网络直播或在活动后30天内观看回放。
09-03 11:30
Banco Bradesco BBI S.A Upgrades Nu Holdings to Outperform, Announces $17 Price Target
Banco Bradesco BBI S.A analyst Marcelo Mizrahi upgrades Nu Holdings (NYSE:NU) from Neutral to Outperform and announces $17 price target.
08-25 23:05
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition
<p>BridgeBio Oncology Therapeutics, Inc. (BBOT) completed its business combination with Helix Acquisition Corp. II on August 11, 2025, closing a $261 million PIPE led by Cormorant Asset Management. Combining this with $120 million from the Helix trust account, BBOT secured approximately $382 million in gross proceeds to advance its RAS-targeted oncology pipeline. BBOT will begin trading on the Nasdaq Global Market under the ticker "BBOT" on Augus...
08-11 20:30
Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
Boundless Bio has announced its Q2 2025 financial results, including $127 million in cash, and highlighted progress in its oncology programs. The POTENTIATE trial's BBI-355/BBI-825 combination arm is now open for enrollment, and BBI-940 is on track for IND submission in H1 2026. The company aims to deliver proof-of-concept data for both programs within its current cash runway, supporting operations into H1 2028. R&D expenses were $12.2 million, a...
08-05 11:00
This Healthcare Stock Surges Around 115%, Here's 74 Biggest Movers From Yesterday
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) shares surged 114.3% to close at $0.2550 on Wednesday after the company announced it has terminated its previously announced at-the-market offering.
2022-06-30 16:55
Brickell Biotech开始进行特应性皮炎治疗的第一阶段试验
09:49 AM EDT, 05/19/2022 (MT Newswires) -- Brickell Biotech (BBI) said Thursday...
2022-05-19 21:54
Brickell Biotech Doses First Subject In Phase 1 Study Of DYRK1A Inhibitor BBI-02
– BBI-02 is a potential first-in-class, oral DYRK1A inhibitor with strong preclinical validation and broad potential to treat debilitating autoimmune and inflammatory diseases – – Topline results from
2022-05-19 20:04
